Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Takeda Pharmaceutical ADR Rep 0.5 Ord Shs V.TAK


Primary Symbol: TAK

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.


NYSE:TAK - Post by User

Post by rory17on Aug 22, 2011 3:49pm
169 Views
Post# 18967953

Legant66

Legant66I agree that Taku has a done a very good job overall, but he fact is there was some insider selling that did not go over well over the last few months with shareholders and more importantly institutional investors, and the drilling is behind schedule, although I believe it will be very successful even this year. The other bone of contention is that senior management was involved in to many other deals like Tahera and Otish which is now Arrowhead Gold. I look at all the facts and will give praise where praise is due and constructive criticism where it is do. Thats why we are at $.19 a share which in my opinion is a very good buy. IMO and GLTA
Bullboard Posts